ATE506957T1 - Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen - Google Patents
Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungenInfo
- Publication number
- ATE506957T1 ATE506957T1 AT07742308T AT07742308T ATE506957T1 AT E506957 T1 ATE506957 T1 AT E506957T1 AT 07742308 T AT07742308 T AT 07742308T AT 07742308 T AT07742308 T AT 07742308T AT E506957 T1 ATE506957 T1 AT E506957T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- prophylactic
- therapeutic agent
- neurodegenerative diseases
- acid sequence
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 230000000069 prophylactic effect Effects 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 229920000155 polyglutamine Polymers 0.000 abstract 2
- 108010040003 polyglutamine Proteins 0.000 abstract 2
- 102000000849 HMGB Proteins Human genes 0.000 abstract 1
- 108010001860 HMGB Proteins Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 238000007792 addition Methods 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000027455 binding Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006154059A JP4982739B2 (ja) | 2006-06-01 | 2006-06-01 | ポリグルタミン病の予防・治療剤 |
| PCT/JP2007/058873 WO2007138810A1 (ja) | 2006-06-01 | 2007-04-24 | 神経変性疾患の予防・治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE506957T1 true ATE506957T1 (de) | 2011-05-15 |
Family
ID=38778331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07742308T ATE506957T1 (de) | 2006-06-01 | 2007-04-24 | Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7833975B2 (de) |
| EP (1) | EP2039367B1 (de) |
| JP (1) | JP4982739B2 (de) |
| AT (1) | ATE506957T1 (de) |
| DE (1) | DE602007014210D1 (de) |
| WO (1) | WO2007138810A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110017371A (ko) | 2008-04-30 | 2011-02-21 | 가부시키가이샤 제노믹스 | 생체내 기능적 세포의 고효율 채취법 |
| KR20120135190A (ko) | 2009-10-28 | 2012-12-12 | 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 | 골수 간엽계 및/또는 다능성 줄기세포의 혈중 동원(動員)에 의한 조직 재생 촉진제 |
| CN103687946B (zh) | 2011-04-26 | 2017-05-03 | 吉诺米克斯股份有限公司 | 用于诱导组织再生的肽及其应用 |
| PL2913058T3 (pl) | 2012-10-25 | 2018-04-30 | Genomix Co., Ltd. | Nowy sposób leczenia zawału mięśnia sercowego przy użyciu fragmentu HMGB1 |
| CN104955470B (zh) | 2012-10-25 | 2017-06-16 | 吉诺米克斯股份有限公司 | 利用了hmgb1片段的针对脊髄损伤的新型治疗方法 |
| WO2015053402A1 (ja) * | 2013-10-11 | 2015-04-16 | 国立大学法人東京医科歯科大学 | 脊髄小脳変性症を予防又は治療するための薬剤 |
| JP6942358B2 (ja) * | 2016-08-09 | 2021-09-29 | 国立大学法人 東京医科歯科大学 | Ｈｍｇｂ１に対する抗体、及びそれを含有するアルツハイマー病を治療又は予防するための組成物 |
| JP6984815B2 (ja) * | 2016-09-12 | 2021-12-22 | 国立大学法人 東京医科歯科大学 | 神経変性疾患タンパク質の異常凝集を伴って発症する神経疾患に対する予防又は治療剤、及び上記予防又は治療剤のスクリーニング方法 |
| BR112019014921A2 (pt) | 2017-01-27 | 2020-03-31 | StemRIM Inc. | Agente terapêutico para miocardiopatia, infarto antigo do miocárdio e insuficiência cardíaca crônica |
| US12421498B2 (en) | 2017-12-01 | 2025-09-23 | StemRIM Inc. | Ectodermal mesenchymal stem cells and method for producing same |
| JPWO2019107530A1 (ja) | 2017-12-01 | 2020-11-26 | 株式会社ステムリム | 炎症性腸疾患の治療薬 |
| WO2019156137A1 (ja) | 2018-02-08 | 2019-08-15 | 株式会社ステムリム | 乾癬の治療薬 |
| US12304933B2 (en) | 2018-10-05 | 2025-05-20 | StemRIM Inc. | Disease treatment drug based on mesenchymal-stem-cell mobilization |
| EP4138878A4 (de) * | 2020-04-22 | 2024-03-20 | Chulalongkorn University | Zusammensetzung und verfahren zur verjüngung von dna und zur verhinderung von dna-schäden |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4255101B2 (ja) | 2002-03-15 | 2009-04-15 | 独立行政法人理化学研究所 | 神経変性疾患の治療薬 |
| EP1579221A2 (de) * | 2003-01-03 | 2005-09-28 | Alcedo Biotech GmbH | Verwendungen von hmgb, hmgn, hmga proteinen |
| WO2005025604A2 (en) * | 2003-09-10 | 2005-03-24 | The General Hospital Corporation | Use of hmgb and hmgb fragments to decrease specific immune response |
| CA2882022A1 (en) * | 2003-09-11 | 2005-03-24 | Walter Newman | Monoclonal antibodies against hmgb1 |
| US7618793B2 (en) * | 2004-10-20 | 2009-11-17 | The Regents Of The University Of Washington | Identifying agents for decreasing cellular toxicity associated with huntingin polypeptide |
-
2006
- 2006-06-01 JP JP2006154059A patent/JP4982739B2/ja active Active
-
2007
- 2007-04-24 DE DE602007014210T patent/DE602007014210D1/de active Active
- 2007-04-24 WO PCT/JP2007/058873 patent/WO2007138810A1/ja not_active Ceased
- 2007-04-24 AT AT07742308T patent/ATE506957T1/de not_active IP Right Cessation
- 2007-04-24 EP EP07742308A patent/EP2039367B1/de active Active
-
2008
- 2008-11-25 US US12/313,837 patent/US7833975B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2039367A4 (de) | 2009-12-30 |
| WO2007138810A1 (ja) | 2007-12-06 |
| US20090280488A1 (en) | 2009-11-12 |
| EP2039367A1 (de) | 2009-03-25 |
| EP2039367B1 (de) | 2011-04-27 |
| US7833975B2 (en) | 2010-11-16 |
| JP4982739B2 (ja) | 2012-07-25 |
| JP2007320919A (ja) | 2007-12-13 |
| DE602007014210D1 (de) | 2011-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE506957T1 (de) | Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen | |
| ATE483027T1 (de) | Rekombinante n-glykosylierte proteine aus prokaryontischen zellen | |
| EA201170878A1 (ru) | Полипептиды с ксиланазной активностью | |
| WO2004078777A3 (en) | Dipeptidyl-peptidase protected proteins | |
| SE0301010D0 (sv) | Novel compounds | |
| SE0301009D0 (sv) | Novel compounds | |
| EP2455459A3 (de) | Lipasevarianten zur pharmazeutischen Verwendung | |
| IN2012DN03368A (de) | ||
| WO2007141274A3 (en) | Human binding molecules having killing activity against staphylococci and uses thereof | |
| WO2008074840A3 (en) | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders | |
| MY138708A (en) | Biaryloxymethylarenecarboxylic acids | |
| ATE417595T1 (de) | Keratin-bindende polypeptide | |
| MX2009006617A (es) | Composiciones que contienen, metodos que involucran y usos de aminoacidos y polipeptidos no naturales. | |
| NO20054769L (no) | Substituerte fenylalkansyrer | |
| MXPA05007182A (es) | Complejos de cristales de proteina y polimeros ionicos. | |
| WO2008061208A3 (en) | Arylsulfonamide compounds | |
| MX2008009493A (es) | Peptido novedoso y uso del mismo. | |
| EP1801206A4 (de) | Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin | |
| WO2008051326A3 (en) | Identification of contactins and l1- cams as ligands for the amyloid precursor protein | |
| WO2005059131A3 (en) | Protein binding miniature proteins and uses thereof | |
| WO2010103515A3 (en) | Compositions and methods for prevention and treatment of neurodegenerative diseases | |
| WO2007132292A3 (en) | Therapy for alzheimer's disease | |
| WO2007145589A8 (en) | Peptides that are capable of binding to amyloid-beta peptide. | |
| WO2008047370A3 (en) | Compositions and methods for inducing angiogenesis | |
| ATE531384T1 (de) | Peptide aus dem plasminogenaktivator-hemmer 1 und ihre verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |